Pricing Log in Create free account

Mesoblast Limited (MESO) vs Stoke Therapeutics, Inc. (STOK)

Mesoblast Limited and Stoke Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Stoke Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Mesoblast Limited grew revenue faster over the last twelve months: −26.5% against −86.3%. Stoke Therapeutics, Inc. has the higher net margin (−862.1% vs −1,091.7%) and the lower return on invested capital (−482.0% vs 0.00%). Across the 17 metrics below, Mesoblast Limited leads on 10 and Stoke Therapeutics, Inc. on 7.

Valuation

Metric MESO STOK Biotechnology median
P/E n/m n/m 11.36
P/S 136.96 64.85 9.12
P/B 1.79 5.19 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 136.55 53.53 8.56
Earnings yield (8.48%) (14.19%) (34.18%)
Free cash flow yield (8.21%) (11.79%) (23.62%)

Profitability

Metric MESO STOK Biotechnology median
Gross margin (269.72%) 100.00% 67.24%
Operating margin (826.28%) (913.12%) 0.00%
Net margin (1,091.71%) (862.07%) 0.00%
Free cash flow margin 0.00% (764.66%) 0.00%
Return on equity 0.00% (73.62%) (50.28%)
Return on assets 0.00% (63.42%) (45.89%)
Return on invested capital 0.00% (482.02%) 0.00%

Growth

Metric MESO STOK Biotechnology median
Revenue growth (TTM) (26.54%) (86.28%) 6.96%
EPS growth (last fiscal year) 48.24% 92.73% 29.86%
Revenue growth, 5-year CAGR 74.39% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO STOK Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 7.24 4.72
Net debt to EBITDA (0.67) 14.29 1.01

Dividend

Metric MESO STOK Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric MESO STOK Biotechnology median
Market cap 1.70b 1.71b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack